Abstract:e21154 Background: EGFR is expressed extensively on epithelial cells, some of stromal cells and even immune cells. However, little is known about systemic impact of EGFR-TKIs on patients with NSCLC and received TKIs treatment. Here we investigated immunological changes and effects on occurred in patients and mice models exposed in EGFR-TKIs. Methods: In order to identify serum biomarkers associated with EGFR-TKIs treatment, we examined 22 samples of NSCLC patients’ serum cytokines at the time of baseline and progressive disease (PD) by cytokine antibody array. C57BL/6 mice (n = 6/group, repeated 3 times) were randomized to Control, Erlotinib (50 mg/kg qd, i.g, 8 weeks), Osimertinib (5 mg/kg qd i.g, 8 weeks), and Afatinib (15 mg/kg qd i.g, 8 weeks). Using flow cytometry, we examined changes of immune cell subsets. Myeloid-derived suppressor cells were analyzed dynamically. Gene expression profile of MDSC and lung tissue were analyzed using RNA Sequencing. Results: Compare to baseline, five cytokines CCL11, CCL15, CXCL7, HGF, GM-CSF were significantly increased in serum of patients achieved PD which associated with MDSC recruitment and expansion. PMN-MDSC accumulation was found in mice bone marrow and spleen in EGFR-TKIs treatment group. Twenty-five immune-related genes expression were significantly increased in EGFR-TKI group (FDR adjusted p < 0.05), such as S100A8 and S100A9 which associated with poor survival in lung adenocarcinoma. In lung tissue from EGFR-TKI-treated mice ,31 immune-related genes differentially expressed. IHC assay manifested the prevalence of PD-L1 expression on alveolar epithelial cells and vascular endothelium was 11% for Control, 72% for Erlotinib, 83% for Afatinib, 44% for Osimertinib. Conclusions: The immune cells and immune microenvironment were changed following EGFR-TKIs treatment. Our study may provide another explanation for poor response to anti-PD-1 or PD-L1 therapy in NSCLC patients with disease progression following EGFR-TKI therapy. Further studies are currently ongoing for testing the elimination of MDSC combining with anti-PD-1 therapy following EGFR-TKI treatment.

Association of Epithelial to Mesenchymal Transition with Efficacy of Egfr-Tkis in Non-Small Cell Lung Cancer Patients with Egfr Wild Type

Epithelial Phenotype As a Predictive Marker for Response to EGFR-TKIs in Non-Small Cell Lung Cancer Patients with Wild-Type EGFR.

P3-015: Clinicopathologic Features and Epidermal Growth Factor Receptor Mutations Associated with Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer

[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer].

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer.

Mir-200C Overexpression is Associated with Better Efficacy of EGFR-TKIs in Non-Small Cell Lung Cancer Patients with EGFR Wild-Type.

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

High Expression of E-cadherin in Pleural Effusion Cells Predicts Better Prognosis in Lung Adenocarcinoma Patients.

Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in Egfr Mutation/Alk Translocation Metastatic Non-Small Cell Lung Cancer

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (Egfr-Tkis) Impact on Immune Microenvironment in Non-Small Cell Lung Cancer (NSCLC).

Epithelial-To-Mesenchymal Transition In Human Esophageal Cancer Associates With Tumor Progression And Patient'S Survival

Clinical Significance of Epithelial-Mesenchymal Transition-Related Molecules in Lung Adenocarcinoma.

Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells

Implication of Epithelial-Mesenchymal Transition in IGF1R-induced Resistance to EGFR-TKIs in Advanced Non-Small Cell Lung Cancer

Prognostic Value of Epithelial-Mesenchymal Transition Markers in Clear Cell Renal Cell Carcinoma.

Epithelial-mesenchymal Transition Markers Screened in a Cell-Based Model and Validated in Lung Adenocarcinoma

The Epithelial-Mesenchymal Transition Phenotype of Metastatic Lymph Nodes Impacts the Prognosis of Esophageal Squamous Cell Carcinoma Patients.

Association of Epithelial-Mesenchymal Transition with Lapatinib Resistance Through Multipe Pathways Activation in Her2-Positive Breast Cancer.